Sickle cell disease: Demystifying the beginnings

Renaissance of Sickle Cell Disease Research in the Genome Era

Volumn , Issue , 2007, Pages 1-12

  Reid, Clarice ^a   Rodgers, Griffin ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967351146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860947964_0001     Document Type: Chapter

References (45)

1. Herrick JB (1910). Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Int Med 6:517-521.
2. Diggs L, Ching RE (1934). Pathology of sickle cell anemia. South Med J 27:839-845.
3. Pauling L, Itano H, Singer SJ, Wells IC (1949). Sickle cell anemia, a molecular disease. Science 110: 543-548.
4. Neel JV (1949). The inheritance of sickle cell anemia. Science 110:164-166.
5. Beet EA (1949). The genetics of the sickle cell trait in a Bantus tribe. Ann Eugen 14:279-284.
6. Ingram VM (1957). Gene mutations in human hemoglobin: the chemical difference between normal and sickle cell hemoglobin. Nature 180:326-328.
7. Perutz MF, Rossman MG, Cullins AF, Muirhead H, Will G, North ACT (1960). Structure of haemoglobin: a three dimensional Fourier synthesis at 5.5, a resolution obtained by X-ray analysis. Nature 185:416-422.
8. Scott R (1970). Health care priority and sickle cell anemia. JAMA 214:731-734.
9. Whitten CF (1973). Sickle cell programming - an imperiled promise. N Engl J Med 288:318-319.
10. Culliton B (1972). Sickle cell anemia: the route from obscurity to prominence. Science 178:140.
11. Scott R (1983). Historical review of legislative and national initiatives for sickle cell disease. Amer J Pediatric Hematology/Oncology 5(4):349.
12. The National Sickle Cell Disease Control Act (1972). Public Law, 92-294.
13. Management and Therapy of Sickle Cell Disease (2002 Revised). US Dept of Health and Human Services. NIH Publication, Rockville, MD. No. 02-2117.
14. Murayama M (1967). Structure of sickle cell hemoglobin and molecular mechanism of the sickling phenomenon. Clin Chem 13:578.
15. Nalbandian RM, Henry RL, Barnhart MI, Nichols BM, Camp FR Jr, Wolf PL (1971). Sickle reversed and blocked by urea in invert sugar. Am J Pathol 65:405-422.
16. McCurdy PR, Mahmood L (1971). Intravenous urea treatment of the painful crisis of sickle cell disease, N Engl J Med 285:992-994.
17. (No authors listed) (1974). Therapy for sickle cell vaso-occlusive crises. Controlled clinical trials and cooperative study of intravenously administered alkali. JAMA 228:1129-1131.
18. Cerami A, Manning JM (1971). Potassium cyanate as an inhibitor of the sickling phenomenon. Proc Natl Acad Sci 68:1180-1183.
19. Harkness D, Roth S (1975). Clinical evaluation of cyanate in sickle cell anemia. Progr Hematol 9:157-184.
20. Deiderich DA, Trueworthy RC, Gill P, Cader AM, Larsen WE (1976). Hematologic and clinical response in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation. J Clin Invest 58: 642-653.
21. Kan YW, Dozy AM (1978). Antenatal diagnosis of sickle-cell anemia by D.N.A. analysis of amniotic fluid cells. Lancet 2:910-912.
22. Serjeant GR, Grandison Y, Lowrie Y, Mason K, Phillips J, Serjeant BE, Vaidya S (1981). The development of haematological changes in homozygous sickle cell disease: a cohort study from birth to six years. Br J Haematol 48:533-543.
23. Powars DR (1975). Natural history of sickle disease: the first ten years. Semin Hematol 12:267.
24. Gaston M, Rosse WF and the Cooperative Group (1982). The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol 4:197-201.
25. Bonds DR (2005). Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Reviews 19:99-110.
26. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS (1986). Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 314:1593-1599.
27. NIH Consensus Conference (1987). Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 258:1205-1209.
28. Pearson HA, O’Brien RT, McIntosh S, Aspnes GT, Yang MM (1974). Routine screening of umbilical cord blood for sickle cell diseases. JAMA 227:420-421.
29. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, Miller ST, Holbrook CT, Kinney TR, Vichinsky E (1995). Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 127:685-690.
30. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR (1991). Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325:11-16.
31. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP (1994). Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
32. Quinn CT, Rogers Z, Buchanan G (2004). Survival of children with sickle cell disease. Blood 103: 4023-4027.
33. Grosveld F, Dillon N, Higgs D (1993). The regulation of human globin gene expression. Balliere’s Clinical Hematology 6:31-55.
34. DeSimone J, Heller P, Hall L, Zwiers D (1982). 5-Azacytidine stimulates fetal hemoglobin sythesis in anemic baboons. Proc Natl Acad Sci USA 79:4428-4431.
35. Ley TJ, DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P, Nienhuis AW (1983). 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62:370-380.
36. Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S (1983). Treatment of sickle cell anemia with 5 aza-cytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA. Proc Natl Acad Sci USA 80:4842-4846.
37. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG (1984). Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Cl Invest 74:652-656.
38. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW (1990). Hematological responses in patients with sickle cell anemia treated with hydroxyurea. N Engl J Med 322:1037-1045.
39. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317-1322.
40. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (2003). Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc 289:1645-1651.
41. Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE (1999). Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS Study, a phase 1/11 trial. Blood 94:1550-1554.
42. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE (2001). A two year pilot of hydroxyurea in very young children with sickle cell anemia. J Pediatr 139:790-796.
43. Russell MO, Goldberg HI, Hudson A, Kim HC (1984). Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 63:162-169.
44. Adams RJ, McKie VJ, Hsu L (1998). Prevention of first stroke by transfusion in children with sickle cell anima and abnormal results on transcranial doppler ultrasonography. N Engl J Med 339:5-11.
45. Saiki RK, Scharf S, Faloma F, Mullis KB, Horn GT, Erlich HA, Arnhein N (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354.